Geron Corporation (GERN)

USD 3.77

(-4.07%)

Market Cap (In USD)

2.27 Billion

Revenue (In USD)

237 Thousand

Net Income (In USD)

-184.12 Million

Avg. Volume

9.16 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.64-5.34
PE
-
EPS
-
Beta Value
0.515
ISIN
US3741631036
CUSIP
374163103
CIK
886744
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John A. Scarlett M.D.
Employee Count
-
Website
https://www.geron.com
Ipo Date
1996-07-31
Details
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.